13F Insight
DOSSIER · 13F-HR · Q1 2026

ARMISTICE CAPITAL, LLC

$5.6B in tracked AUM across 267 positions as of Q1 2026.

AC
CIK 0001601086 · last filed Mar 31, 2026
Total AUM
$5.6B
as of Q1 2026
Holdings
267
—
positions
Whale Score
67
67
tracked
Activity
—
no data
changes this Q
AI Analysis · Q1 2026
Comprehensive Analysis of Armistice Capital, LLC 13F Filing (Q3 2025)
Portfolio Overview

Armistice Capital, LLC reported a significant contraction in portfolio value during the quarter ending September 30, 2025. The total assets under management (AUM) decreased by 33.7%, dropping from $5.80 billion to $3.84 billion. This reduction is not solely attributable to market performance but indicates a substantial shift in capital allocation or risk management strategy. The number of ...

Key Holdings

The most striking feature of this filing is the dominance of the top position: SPY (SPDR S&P 500 ETF Trust). However, the specific listing "SPY OCT5 634.0 P" indicates this is a put option position rather than a long equity holding. Valued at $1.67 billion, this single position constitutes 43.37% of the entire portfolio. This suggests the firm is heavily hedged against market downside or is speculating on a market decline by the October 2025 expiration.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q1 2026. Methodology

Quarter at a glance — Q1 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q1 2026.

#HoldingValueSharesWeight
01
SPY
STATE STR SPDR S&P 500 ETF T
$1.4B2.1M24.3%02
IWM
ISHARES TR
$868M3.5M15.4%03
AGIO
AGIOS PHARMACEUTICALS INC
$200M5.9M3.6%04
CYTK
CYTOKINETICS INC
$176M2.7M3.1%05
PTCT
PTC THERAPEUTICS INC
$168M2.5M3.0%06
TVTX
TRAVERE THERAPEUTICS INC
$146M4.9M2.6%07
MDGL
MADRIGAL PHARMACEUTICALS INC
$139M265K2.5%08
IMVT
IMMUNOVANT INC
$136M5.5M2.4%09
SUPN
SUPERNUS PHARMACEUTICALS
$98M1.9M1.7%10
NBIX
NEUROCRINE BIOSCIENCES INC
$95M724K1.7%

Filing history

2026Q1Mar 31
$5.6B▼ 33.1%
267 positionsView →2025Q4Dec 31
$8.4B▲ 118.9%
370 positionsView →2025Q3Sep 30
$3.8B▼ 33.7%
187 positionsView →2025Q2Jun 30
$5.8B▲ 43.4%
210 positionsLocked2025Q1Mar 31
$4.0B▼ 44.9%
142 positionsLocked2024Q4Dec 31
$7.3B▲ 17.2%
232 positionsLocked2024Q3Sep 30
$6.3B▼ 21.3%
259 positionsLocked2024Q2Jun 30
$7.9B▲ 5.4%
254 positionsLocked2024Q1Mar 31
$7.5B▲ 2.9%
337 positionsLocked2023Q4Dec 31
$7.3B▲ 12.2%
297 positionsLocked2023Q3Sep 30
$6.5B▼ 5.5%
254 positionsLocked2023Q2Jun 30
$6.9B▼ 0.5%
222 positionsLocked
Showing 12 of 43